{"success":true,"data":{"pressRelease":{"id":"167411","rtpr_id":"nBwbHHY9fa-20261013","ticker":"BIAF","exchange":"NASDAQ","all_tickers":["BIAF","BIAFW"],"title":"bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026","author":"Business Wire","published_at":"2026-10-13T12:00:00.343Z","article_body":"bioAffinity Technologies to Present Positive Research Data in Development of\nIts New Test Measuring Asthma and COPD-Related Lung Inflammation and\nDrug-Related Receptors at CHEST 2026\n\nFindings report on ability to measure cellular and soluble inflammatory\nprotein biomarkers in sputum, including biologic drug targets\n\nCompany advances research and development in diagnostic tests for major lung\ndiseases building on CyPath® Lung + AI foundation\n\nGlobal asthma therapeutics market projected to reach $47.6 billion by 2034\n\nbioAffinity Technologies\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbioaffinitytech.com%2F&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=bioAffinity+Technologies&index=1&md5=d7255578f827953d9ed576c6730654b9)\n, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive\nhealthcare solutions for the early detection and monitoring of lung disease,\ntoday announced it will present new data at CHEST 2026\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.chestnet.org%2Flearning-and-events%2Fevents%2Fchest-annual-meeting%3F%26utm_medium%3Dppc%26utm_source%3Dgoogle%26utm_campaign%3Dannual-meeting%26gad_source%3D1&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=CHEST+2026&index=2&md5=9a709fa30c8f7d1e4d789b9b08d59057)\n, the annual meeting of the American College of Chest Physicians, on the\nCompany's sputum-based tests in development to characterize lung inflammation\nand detect multiple protein biomarkers of lung inflammation, including\nbiologic drug targets of therapeutics used to treat asthma and chronic\nobstructive pulmonary disease (COPD).\n\nBy providing a more complete picture of a patient's inflammatory profile, this\nresearch approach may, with further development and validation, help inform\nidentification of patients who could benefit from specific biologic therapies\nand support monitoring of lung inflammation over time, consistent with a\nprecision medicine approach.\n\nbioAffinity Technologies will present a poster, titled \"Sputum as a Diagnostic\nTool for the Measurement of Lung Inflammation in Asthma,\" that describes a\nworkflow based on the proprietary flow cytometry + AI platform used by the\nCompany's commercially available noninvasive CyPath® Lung\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cypathlung.com&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=CyPath%26%23174%3B+Lung&index=3&md5=04c1f3e9c00c352fa9eab2e9e8df7980)\ndiagnostic for lung cancer.\n\nThe poster reports research on measuring key cytokines and cell-surface\nreceptors involved in lung inflammation, including targets of approved and\nemerging biologic therapies for asthma and COPD. Data show that the test in\ndevelopment can detect multiple targets in sputum using a combination of\ncellular and proteomic analysis. Data are specifically provided for soluble\nand cellular biologic drug targets that play different roles in driving\ninflammation:\n\n\n * TSLP: an epithelial alarmin that is an early trigger of inflammation. It is\ntargeted by tezepelumab (\nTezspire\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.tezspire.com%2F%3Fsource%3DTZP_N_C_282%26umedium%3Dcpc%26uadpub%3DGOOGLE%26ucampaign%3DUSA_GO_SEM_DTC_B_EX_Brand-Tezspire%26ucreative%3DCore%26uplace%3Dtezspire%26outcome%3DDTC%26cmpid%3D1%26gclid%3DCjwKCAjw56zWBhB0EiwAdPOQObNEK5cJSb-GMzTD-B3zvG53TcGd6okdxKGaT7StiQul6suxgvBdFRoCeQUQAvD_BwE%26gclsrc%3Daw.ds%26gad_source%3D1%26gad_campaignid%3D15619743754%26gbraid%3D0AAAAAoTTh392QY16eRDyCd86AwW1NaAzP&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=Tezspire&index=4&md5=44f279241da6f743204dacaf077211e0)\n\n) and related drugs.\n\n * CRLF2: a cell-surface receptor for TSLP targeted by the investigational\ntherapeutic \nverkitug\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fupstreambio.com%2Fpipeline%2F&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=verkitug&index=5&md5=121bb39a191997a46b528cb106837e1e)\n\n.\n\n * IL4-Ra (CD124): a receptor subunit present in IL-4 and IL-13 receptors\ninvolved in Th2 asthma inflammation and some forms of COPD. It is targeted by\ndupilumab (\nDupixent\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.dupixent.com%2F&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=Dupixent&index=6&md5=b1fcb8bd11003c69759533b9a987290f)\n\n).\n\n * IL-5: a cytokine that promotes the growth and activity of eosinophils, immune\ncells involved in eosinophilic asthma and some COPD. It is targeted by\nmepolizumab (\nNucala\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nucala.com%2Fcopd%2F%3Fcc%3Dps_7D0IITHB483408089%26mtrc%3D500418%26mcm%3D500418%26gclsrc%3Daw.ds%26gad_source%3D1%26gad_campaignid%3D22526690540%26gbraid%3D0AAAAA_fW9SixpjC-KVTQeHxT1NSMC8frE%26gclid%3DCjwKCAjw56zWBhB0EiwAdPOQOY21r5ZSBOcmfe_YA1Tiy7LfSzQ-GbH0LB-TsVaxIwxkqn6n-_ZGrxoCTSAQAvD_BwE&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=Nucala&index=7&md5=e4906174b3e591a2cb87fed5bb257489)\n\n).\n\nReferences to these and other branded therapeutics identify biological\npathways and drug targets studied in the research and do not constitute a\nclaim that the Company's test in development can be used to select, guide,\nmonitor or otherwise inform the use of any named therapy. The test described\nis investigational and not yet available for clinical or diagnostic use.\n\nAccording to the Asthma and Allergy Foundation of America(1), an estimated 28\nmillion Americans have asthma, including 5 million children, or seven out of\n100 people under the age of 18. In 2020, asthma accounted for nearly 100,000\ndischarges from hospital inpatient care and almost 1 million emergency\ndepartment visits. The global asthma therapeutics market is estimated at\napproximately $29.7 billion in 2025, projected to reach $47.6 billion by\n2034.(2) The market includes a growing range of biologic therapies that target\nspecific pathways involved in inflammation.\n\n\"Lung inflammation in asthma is complex and heterogeneous, and clinicians need\nbetter tools to characterize what is happening in the lung and understand\ndifferences among patients,\" said Gordon Downie, MD, PhD, bioAffinity\nTechnologies Chief Medical Officer. \"We believe this research represents an\nimportant step toward a better understanding of distinct types of lung\ninflammation and targeted treatment specific to each patient.\"\n\nDr. Downie will lead a discussion at CHEST 2026 on the clinical use of CyPath\nLung and the development of sputum-based tests to characterize lung\ninflammation in patients with asthma and COPD. The discussion will take place\nin Learning Theater 4 at 12:30 p.m. on October 21.\n\nIn the study, sputum samples were collected from people with asthma, smokers\nwithout asthma, smokers with COPD, a smoker with both COPD and asthma, and\nhealthy individuals. Immune cell populations were analyzed by flow cytometry\nand inflammatory proteins (cytokines) were measured by an enzyme-linked\nimmunosorbent assay (ELISA). The combined data were analyzed using machine\nlearning.\n\nBy measuring the inflammatory markers in sputum, the Company’s ongoing\nresearch aims to improve understanding of different patterns of lung\ninflammation, with the goal of ultimately helping identify and monitor\npatients who may be most likely to benefit from specific treatments, subject\nto further research and validation.\n\n\"Our research shows the potential to measure cellular and protein features\ndirectly from sputum, including selected targets associated with specific\nbiologic drugs,\" said William Bauta, PhD, bioAffinity Technologies Chief\nScience Officer. \"We believe this test could provide a more detailed picture\nof lung inflammation and, with further study, help doctors discern among\ntreatment options and track inflammatory changes in the lung over time.\"\n\nCHEST 2026 Presentation Details\n\nTitle: Sputum as a Diagnostic Tool for the Measurement of Lung Inflammation in\nAsthma\n\nPoster: 3071\n\nSession: Original Investigation / Allergy-Airway\n\nDate: October 20, 2026\n\nTime: 1:45–2:30 p.m.\n\nLocation: Phoenix Convention Center, Phoenix, AZ\n\nAbout CyPath Lung\n\nCyPath Lung by bioAffinity Technologies is a noninvasive test designed to\nimprove the early detection of lung cancer in patients at high risk for the\ndisease. CyPath Lung uses advanced flow cytometry and proprietary artificial\nintelligence (AI) to identify cell populations in patient sputum that indicate\nmalignancy. CyPath Lung incorporates a novel fluorescent porphyrin that is\npreferentially taken up by cancer and cancer-related cells. In a published\nclinical trial\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2Fs12931-023-02327-3&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=published+clinical+trial&index=8&md5=2414f2f32ff7c0a8729a8204baa7a8bc)\nof high-risk patients, CyPath Lung demonstrated 92% sensitivity, 87%\nspecificity, 88% accuracy and 99% negative predictive value (NPV) in detecting\nlung cancer in patients at high risk for the disease who had small\nindeterminate lung nodules less than 20 millimeters. The high NPV may help\ninform physician decision-making when evaluating whether further invasive\nprocedures are warranted. CyPath Lung is marketed as a Laboratory Developed\nTest (LDT), is not intended for use as a sole diagnostic tool, and should be\nconsidered alongside other clinical findings. For more information, visit\nwww.cypathlung.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cypathlung.com%2F&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=www.cypathlung.com&index=9&md5=ab365f79a21afb7c4342cf3159d6af17)\n.\n\nAbout bioAffinity Technologies, Inc.\n\nbioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of\nearly-stage cancer and other diseases of the lung and broad-spectrum cancer\ntreatments. The Company’s first product, CyPath Lung, is a noninvasive test\nthat has shown high sensitivity, specificity and accuracy for the detection of\nearly-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed\nTest (LDT) by Precision Pathology Laboratory Services, a subsidiary of\nbioAffinity Technologies. LDTs are overseen under the Clinical Laboratory\nImprovement Amendments (CLIA), which are administered by the Centers for\nMedicare & Medicaid Services. For more information, visit\nwww.bioaffinitytech.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bioaffinitytech.com&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=www.bioaffinitytech.com&index=10&md5=27af6f40e224f48c1079aed64ed9b154)\n.\n\nForward-Looking Statements\n\nCertain statements in this press release constitute \"forward-looking\nstatements\" within the meaning of the federal securities laws. Words such as\n\"may,\" \"might,\" \"will,\" \"should,\" \"believe,\" \"expect,\" \"anticipate,\"\n\"estimate,\" \"continue,\" \"predict,\" \"forecast,\" \"project,\" \"plan,\" \"intend\" or\nsimilar expressions, or statements regarding intent, belief, or current\nexpectations, are forward-looking statements. These forward-looking statements\nare subject to various risks and uncertainties, many of which are difficult to\npredict, that could cause actual results to differ materially from current\nexpectations and assumptions from those set forth or implied by any\nforward-looking statements. Forward-looking statements in this press release\ninclude, but are not limited to, statements regarding: the Company's research\nand development of sputum-based tests to characterize lung inflammation and\ndetect protein biomarkers, including biologic drug targets, for asthma and\nCOPD; the potential clinical utility, benefits, or future availability of such\ntests, including their potential to help identify or monitor patients who may\nbenefit from specific biologic therapies or to support a precision medicine\napproach; the Company's plans and expectations regarding ongoing research,\ndevelopment, and validation of its sputum-based tests; expectations regarding\nthe content and conclusions of the poster presentation and discussion at CHEST\n2026; projections of the global asthma therapeutics market size, including the\nestimate that the market will reach $47.6 billion by 2034; and other factors\ndiscussed in the Company’s Annual Report on Form 10-K for the year ended\nDecember 31, 2025, and its subsequent filings with the SEC, including\nsubsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking\nstatements are based on facts and conditions as they exist at the time such\nstatements are made and predictions as to future facts and conditions. While\nthe Company believes these forward-looking statements are reasonable, readers\nof this press release are cautioned not to place undue reliance on any\nforward-looking statements. The information in this release is provided only\nas of the date of this release, and the Company does not undertake any\nobligation to update any forward-looking statement relating to matters\ndiscussed in this press release, except as may be required by applicable\nsecurities laws.\n         \n\n\n(1) Asthma and Allergy Foundation of America, Asthma Fact and Figures \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faafa.org%2Fwp-content%2Fuploads%2F2025%2F04%2Faafa-asthma-facts-and-figures.pdf&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=Asthma+Fact+and+Figures&index=11&md5=9e5c903128cf677b093de39ff27c5470)\n\n(2) Fortune Business Insights, Asthma Therapeutics Market Size, Share &\nIndustry Analysis\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.fortunebusinessinsights.com%2Fasthma-therapeutics-market-116788&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=Asthma+Therapeutics+Market+Size%2C+Share+%26amp%3B+Industry+Analysis&index=12&md5=fbd4f7d1757f8f24982d38f9ecb207e5)\n, September 2026\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261013780632/en/\n(https://www.businesswire.com/news/home/20261013780632/en/)\n\nbioAffinity Technologies\n\nJulie Anne Overton\n\nDirector of Communications\n\ninvestors@bioaffinitytech.com (mailto:investors@bioaffinitytech.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwbHHY9fa-20261013","title":"bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026","author":"Business Wire","ticker":"BIAF","created":"2026-10-13T12:00:00.343Z","tickers":["BIAF","BIAFW"],"exchange":"NASDAQ","article_body":"bioAffinity Technologies to Present Positive Research Data in Development of\nIts New Test Measuring Asthma and COPD-Related Lung Inflammation and\nDrug-Related Receptors at CHEST 2026\n\nFindings report on ability to measure cellular and soluble inflammatory\nprotein biomarkers in sputum, including biologic drug targets\n\nCompany advances research and development in diagnostic tests for major lung\ndiseases building on CyPath® Lung + AI foundation\n\nGlobal asthma therapeutics market projected to reach $47.6 billion by 2034\n\nbioAffinity Technologies\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbioaffinitytech.com%2F&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=bioAffinity+Technologies&index=1&md5=d7255578f827953d9ed576c6730654b9)\n, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive\nhealthcare solutions for the early detection and monitoring of lung disease,\ntoday announced it will present new data at CHEST 2026\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.chestnet.org%2Flearning-and-events%2Fevents%2Fchest-annual-meeting%3F%26utm_medium%3Dppc%26utm_source%3Dgoogle%26utm_campaign%3Dannual-meeting%26gad_source%3D1&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=CHEST+2026&index=2&md5=9a709fa30c8f7d1e4d789b9b08d59057)\n, the annual meeting of the American College of Chest Physicians, on the\nCompany's sputum-based tests in development to characterize lung inflammation\nand detect multiple protein biomarkers of lung inflammation, including\nbiologic drug targets of therapeutics used to treat asthma and chronic\nobstructive pulmonary disease (COPD).\n\nBy providing a more complete picture of a patient's inflammatory profile, this\nresearch approach may, with further development and validation, help inform\nidentification of patients who could benefit from specific biologic therapies\nand support monitoring of lung inflammation over time, consistent with a\nprecision medicine approach.\n\nbioAffinity Technologies will present a poster, titled \"Sputum as a Diagnostic\nTool for the Measurement of Lung Inflammation in Asthma,\" that describes a\nworkflow based on the proprietary flow cytometry + AI platform used by the\nCompany's commercially available noninvasive CyPath® Lung\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cypathlung.com&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=CyPath%26%23174%3B+Lung&index=3&md5=04c1f3e9c00c352fa9eab2e9e8df7980)\ndiagnostic for lung cancer.\n\nThe poster reports research on measuring key cytokines and cell-surface\nreceptors involved in lung inflammation, including targets of approved and\nemerging biologic therapies for asthma and COPD. Data show that the test in\ndevelopment can detect multiple targets in sputum using a combination of\ncellular and proteomic analysis. Data are specifically provided for soluble\nand cellular biologic drug targets that play different roles in driving\ninflammation:\n\n\n * TSLP: an epithelial alarmin that is an early trigger of inflammation. It is\ntargeted by tezepelumab (\nTezspire\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.tezspire.com%2F%3Fsource%3DTZP_N_C_282%26umedium%3Dcpc%26uadpub%3DGOOGLE%26ucampaign%3DUSA_GO_SEM_DTC_B_EX_Brand-Tezspire%26ucreative%3DCore%26uplace%3Dtezspire%26outcome%3DDTC%26cmpid%3D1%26gclid%3DCjwKCAjw56zWBhB0EiwAdPOQObNEK5cJSb-GMzTD-B3zvG53TcGd6okdxKGaT7StiQul6suxgvBdFRoCeQUQAvD_BwE%26gclsrc%3Daw.ds%26gad_source%3D1%26gad_campaignid%3D15619743754%26gbraid%3D0AAAAAoTTh392QY16eRDyCd86AwW1NaAzP&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=Tezspire&index=4&md5=44f279241da6f743204dacaf077211e0)\n\n) and related drugs.\n\n * CRLF2: a cell-surface receptor for TSLP targeted by the investigational\ntherapeutic \nverkitug\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fupstreambio.com%2Fpipeline%2F&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=verkitug&index=5&md5=121bb39a191997a46b528cb106837e1e)\n\n.\n\n * IL4-Ra (CD124): a receptor subunit present in IL-4 and IL-13 receptors\ninvolved in Th2 asthma inflammation and some forms of COPD. It is targeted by\ndupilumab (\nDupixent\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.dupixent.com%2F&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=Dupixent&index=6&md5=b1fcb8bd11003c69759533b9a987290f)\n\n).\n\n * IL-5: a cytokine that promotes the growth and activity of eosinophils, immune\ncells involved in eosinophilic asthma and some COPD. It is targeted by\nmepolizumab (\nNucala\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nucala.com%2Fcopd%2F%3Fcc%3Dps_7D0IITHB483408089%26mtrc%3D500418%26mcm%3D500418%26gclsrc%3Daw.ds%26gad_source%3D1%26gad_campaignid%3D22526690540%26gbraid%3D0AAAAA_fW9SixpjC-KVTQeHxT1NSMC8frE%26gclid%3DCjwKCAjw56zWBhB0EiwAdPOQOY21r5ZSBOcmfe_YA1Tiy7LfSzQ-GbH0LB-TsVaxIwxkqn6n-_ZGrxoCTSAQAvD_BwE&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=Nucala&index=7&md5=e4906174b3e591a2cb87fed5bb257489)\n\n).\n\nReferences to these and other branded therapeutics identify biological\npathways and drug targets studied in the research and do not constitute a\nclaim that the Company's test in development can be used to select, guide,\nmonitor or otherwise inform the use of any named therapy. The test described\nis investigational and not yet available for clinical or diagnostic use.\n\nAccording to the Asthma and Allergy Foundation of America(1), an estimated 28\nmillion Americans have asthma, including 5 million children, or seven out of\n100 people under the age of 18. In 2020, asthma accounted for nearly 100,000\ndischarges from hospital inpatient care and almost 1 million emergency\ndepartment visits. The global asthma therapeutics market is estimated at\napproximately $29.7 billion in 2025, projected to reach $47.6 billion by\n2034.(2) The market includes a growing range of biologic therapies that target\nspecific pathways involved in inflammation.\n\n\"Lung inflammation in asthma is complex and heterogeneous, and clinicians need\nbetter tools to characterize what is happening in the lung and understand\ndifferences among patients,\" said Gordon Downie, MD, PhD, bioAffinity\nTechnologies Chief Medical Officer. \"We believe this research represents an\nimportant step toward a better understanding of distinct types of lung\ninflammation and targeted treatment specific to each patient.\"\n\nDr. Downie will lead a discussion at CHEST 2026 on the clinical use of CyPath\nLung and the development of sputum-based tests to characterize lung\ninflammation in patients with asthma and COPD. The discussion will take place\nin Learning Theater 4 at 12:30 p.m. on October 21.\n\nIn the study, sputum samples were collected from people with asthma, smokers\nwithout asthma, smokers with COPD, a smoker with both COPD and asthma, and\nhealthy individuals. Immune cell populations were analyzed by flow cytometry\nand inflammatory proteins (cytokines) were measured by an enzyme-linked\nimmunosorbent assay (ELISA). The combined data were analyzed using machine\nlearning.\n\nBy measuring the inflammatory markers in sputum, the Company’s ongoing\nresearch aims to improve understanding of different patterns of lung\ninflammation, with the goal of ultimately helping identify and monitor\npatients who may be most likely to benefit from specific treatments, subject\nto further research and validation.\n\n\"Our research shows the potential to measure cellular and protein features\ndirectly from sputum, including selected targets associated with specific\nbiologic drugs,\" said William Bauta, PhD, bioAffinity Technologies Chief\nScience Officer. \"We believe this test could provide a more detailed picture\nof lung inflammation and, with further study, help doctors discern among\ntreatment options and track inflammatory changes in the lung over time.\"\n\nCHEST 2026 Presentation Details\n\nTitle: Sputum as a Diagnostic Tool for the Measurement of Lung Inflammation in\nAsthma\n\nPoster: 3071\n\nSession: Original Investigation / Allergy-Airway\n\nDate: October 20, 2026\n\nTime: 1:45–2:30 p.m.\n\nLocation: Phoenix Convention Center, Phoenix, AZ\n\nAbout CyPath Lung\n\nCyPath Lung by bioAffinity Technologies is a noninvasive test designed to\nimprove the early detection of lung cancer in patients at high risk for the\ndisease. CyPath Lung uses advanced flow cytometry and proprietary artificial\nintelligence (AI) to identify cell populations in patient sputum that indicate\nmalignancy. CyPath Lung incorporates a novel fluorescent porphyrin that is\npreferentially taken up by cancer and cancer-related cells. In a published\nclinical trial\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2Fs12931-023-02327-3&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=published+clinical+trial&index=8&md5=2414f2f32ff7c0a8729a8204baa7a8bc)\nof high-risk patients, CyPath Lung demonstrated 92% sensitivity, 87%\nspecificity, 88% accuracy and 99% negative predictive value (NPV) in detecting\nlung cancer in patients at high risk for the disease who had small\nindeterminate lung nodules less than 20 millimeters. The high NPV may help\ninform physician decision-making when evaluating whether further invasive\nprocedures are warranted. CyPath Lung is marketed as a Laboratory Developed\nTest (LDT), is not intended for use as a sole diagnostic tool, and should be\nconsidered alongside other clinical findings. For more information, visit\nwww.cypathlung.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cypathlung.com%2F&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=www.cypathlung.com&index=9&md5=ab365f79a21afb7c4342cf3159d6af17)\n.\n\nAbout bioAffinity Technologies, Inc.\n\nbioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of\nearly-stage cancer and other diseases of the lung and broad-spectrum cancer\ntreatments. The Company’s first product, CyPath Lung, is a noninvasive test\nthat has shown high sensitivity, specificity and accuracy for the detection of\nearly-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed\nTest (LDT) by Precision Pathology Laboratory Services, a subsidiary of\nbioAffinity Technologies. LDTs are overseen under the Clinical Laboratory\nImprovement Amendments (CLIA), which are administered by the Centers for\nMedicare & Medicaid Services. For more information, visit\nwww.bioaffinitytech.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bioaffinitytech.com&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=www.bioaffinitytech.com&index=10&md5=27af6f40e224f48c1079aed64ed9b154)\n.\n\nForward-Looking Statements\n\nCertain statements in this press release constitute \"forward-looking\nstatements\" within the meaning of the federal securities laws. Words such as\n\"may,\" \"might,\" \"will,\" \"should,\" \"believe,\" \"expect,\" \"anticipate,\"\n\"estimate,\" \"continue,\" \"predict,\" \"forecast,\" \"project,\" \"plan,\" \"intend\" or\nsimilar expressions, or statements regarding intent, belief, or current\nexpectations, are forward-looking statements. These forward-looking statements\nare subject to various risks and uncertainties, many of which are difficult to\npredict, that could cause actual results to differ materially from current\nexpectations and assumptions from those set forth or implied by any\nforward-looking statements. Forward-looking statements in this press release\ninclude, but are not limited to, statements regarding: the Company's research\nand development of sputum-based tests to characterize lung inflammation and\ndetect protein biomarkers, including biologic drug targets, for asthma and\nCOPD; the potential clinical utility, benefits, or future availability of such\ntests, including their potential to help identify or monitor patients who may\nbenefit from specific biologic therapies or to support a precision medicine\napproach; the Company's plans and expectations regarding ongoing research,\ndevelopment, and validation of its sputum-based tests; expectations regarding\nthe content and conclusions of the poster presentation and discussion at CHEST\n2026; projections of the global asthma therapeutics market size, including the\nestimate that the market will reach $47.6 billion by 2034; and other factors\ndiscussed in the Company’s Annual Report on Form 10-K for the year ended\nDecember 31, 2025, and its subsequent filings with the SEC, including\nsubsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking\nstatements are based on facts and conditions as they exist at the time such\nstatements are made and predictions as to future facts and conditions. While\nthe Company believes these forward-looking statements are reasonable, readers\nof this press release are cautioned not to place undue reliance on any\nforward-looking statements. The information in this release is provided only\nas of the date of this release, and the Company does not undertake any\nobligation to update any forward-looking statement relating to matters\ndiscussed in this press release, except as may be required by applicable\nsecurities laws.\n         \n\n\n(1) Asthma and Allergy Foundation of America, Asthma Fact and Figures \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faafa.org%2Fwp-content%2Fuploads%2F2025%2F04%2Faafa-asthma-facts-and-figures.pdf&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=Asthma+Fact+and+Figures&index=11&md5=9e5c903128cf677b093de39ff27c5470)\n\n(2) Fortune Business Insights, Asthma Therapeutics Market Size, Share &\nIndustry Analysis\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.fortunebusinessinsights.com%2Fasthma-therapeutics-market-116788&esheet=54620689&newsitemid=20261013780632&lan=en-US&anchor=Asthma+Therapeutics+Market+Size%2C+Share+%26amp%3B+Industry+Analysis&index=12&md5=fbd4f7d1757f8f24982d38f9ecb207e5)\n, September 2026\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261013780632/en/\n(https://www.businesswire.com/news/home/20261013780632/en/)\n\nbioAffinity Technologies\n\nJulie Anne Overton\n\nDirector of Communications\n\ninvestors@bioaffinitytech.com (mailto:investors@bioaffinitytech.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-13T12:00:00.59676176Z","server_sent_at_ms":1791892800596},"received_at":"2026-10-13T12:00:00.648Z","source_url":"https://www.businesswire.com/news/home/20261013780632/en/"},"analysis":{"id":"155715","press_release_id":"167411","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["test in development is investigational and not available for clinical or diagnostic use","company explicitly disclaims that the test can select or guide use of any named therapy","market-size figures are third-party projections, not company revenue drivers yet"],"eventType":"operations_update","narrative":"bioAffinity Technologies will present new data at CHEST 2026 on a sputum-based test in development that measures lung inflammation biomarkers, including biologic drug targets for asthma and COPD.\n\nThe poster builds on the flow cytometry + AI platform behind its commercial CyPath Lung test, detecting targets such as TSLP, CRLF2, IL4-Ra, and IL-5 in sputum samples.\n\nThe test remains investigational and not available for clinical use; any commercial application requires further development and validation. The company cites a global asthma therapeutics market projected to reach $47.6 billion by 2034.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Early-stage data showing platform expansion beyond lung cancer into asthma/COPD inflammation testing -- pipeline optionality, not near-term revenue."},"keyFigures":{"customDimensions":{"cypath_lung_npv":"99%","asthma_market_2025":"$29.7 billion","us_asthma_patients":"28 million","cypath_lung_sensitivity":"92%","cypath_lung_specificity":"87%","asthma_market_2034_projection":"$47.6 billion"}},"quotedText":"Lung inflammation in asthma is complex and heterogeneous, and clinicians need better tools to characterize what is happening in the lung and understand differences among patients","namedEntities":{"people":[{"name":"Gordon Downie","role":"Chief Medical Officer"},{"name":"William Bauta","role":"Chief Science Officer"},{"name":"Julie Anne Overton","role":"Director of Communications"}],"products":["CyPath Lung","Tezspire (tezepelumab)","verkitug","Dupixent (dupilumab)","Nucala (mepolizumab)"],"companies":[{"name":"bioAffinity Technologies, Inc.","ticker":"BIAF"},{"name":"Precision Pathology Laboratory Services","relationship":"subsidiary"},{"name":"American College of Chest Physicians","relationship":"conference host"}],"dollarAmounts":[{"amount":"$47.6 billion","context":"projected global asthma therapeutics market by 2034"},{"amount":"$29.7 billion","context":"estimated global asthma therapeutics market in 2025"}]},"materialImpact":{"score":2,"reasoning":"Positive early research data for an investigational sputum-based diagnostic being presented at CHEST 2026. The test is not commercially available, no revenue or regulatory milestone is attached, and the company itself cautions the test is investigational."},"tickerRelevance":{"others":[],"primary":"BIAF"},"globalImportance":12,"audienceRelevance":10,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference-poster-data","issuerAuthored":true,"commercialStage":"pre-revenue-pipeline"}},"event_type":"operations_update","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":2,"narrative":"bioAffinity Technologies will present new data at CHEST 2026 on a sputum-based test in development that measures lung inflammation biomarkers, including biologic drug targets for asthma and COPD.\n\nThe poster builds on the flow cytometry + AI platform behind its commercial CyPath Lung test, detecting targets such as TSLP, CRLF2, IL4-Ra, and IL-5 in sputum samples.\n\nThe test remains investigational and not available for clinical use; any commercial application requires further development and validation. The company cites a global asthma therapeutics market projected to reach $47.6 billion by 2034.","key_figures":{"customDimensions":{"cypath_lung_npv":"99%","asthma_market_2025":"$29.7 billion","us_asthma_patients":"28 million","cypath_lung_sensitivity":"92%","cypath_lung_specificity":"87%","asthma_market_2034_projection":"$47.6 billion"}},"named_entities":{"people":[{"name":"Gordon Downie","role":"Chief Medical Officer"},{"name":"William Bauta","role":"Chief Science Officer"},{"name":"Julie Anne Overton","role":"Director of Communications"}],"products":["CyPath Lung","Tezspire (tezepelumab)","verkitug","Dupixent (dupilumab)","Nucala (mepolizumab)"],"companies":[{"name":"bioAffinity Technologies, Inc.","ticker":"BIAF"},{"name":"Precision Pathology Laboratory Services","relationship":"subsidiary"},{"name":"American College of Chest Physicians","relationship":"conference host"}],"dollarAmounts":[{"amount":"$47.6 billion","context":"projected global asthma therapeutics market by 2034"},{"amount":"$29.7 billion","context":"estimated global asthma therapeutics market in 2025"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T12:00:06.733Z","global_importance":12,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference-poster-data","issuerAuthored":true,"commercialStage":"pre-revenue-pipeline"}},"durationMs":6044,"modelName":"glm-5.3-flashx"}}